Skydance's Warner Bros. Deal Creates Scale—and a Heavy Debt Test

Amazon shares rose after Morgan Stanley named the company a top pick and raised its price target to $350 from $335. The target is not simply a bet on faster cloud demand. It assumes that Amazon Web Services can turn a much larger capital program into expanding margins and earnings.

The analyst's model calls for AWS revenue growth of 47% in 2027 and 42% in 2028, supported by additional Nvidia GPU deployments. It also assumes AWS margins rise to 42% in 2027 and 44% in 2028. Those estimates lead to roughly $16.50 of earnings per share in 2028, putting the $350 target at about 21 times that forecast.

The spending side is just as important. Morgan Stanley projects capital expenditures of $355 billion in 2027 and $365 billion in 2028, far above current consensus. That creates a demanding test: newly installed equipment must generate revenue quickly enough to cover depreciation, power and operating costs without eroding cloud profitability.

Amazon's own investor-relations calendar says third-quarter results are due on October 29. The prior quarter gave bulls evidence to work with, including AWS growth of about 37% and a 39.3% segment margin. Yet one strong quarter cannot validate a multi-year model whose earnings estimate sits well above consensus.

The cleanest way to assess the call is to separate demand from returns. Backlog and GPU availability can show that customers want more capacity. AWS operating margin and companywide free cash flow show whether Amazon is earning an adequate return on the build-out. Both need to improve for the most optimistic forecasts to hold.

At roughly $262 before the call, the stock was already less than 30% below Morgan Stanley's target. The remaining upside therefore depends less on multiple expansion than on the bank's above-consensus earnings path. Investors should treat the $350 figure as the output of aggressive assumptions, not as an independent fact.

Eli Lilly's obesity and diabetes portfolio is producing exceptional growth, but the next phase will test whether volume can outrun pricing pressure and the cost of expanding supply.

Second-quarter 2026 revenue rose 48% to $22.97 billion. Reported earnings were $7.94 a share and non-GAAP earnings were $8.38, including $3.03 a share of acquired research and development charges. Lilly raised full-year revenue guidance to $85 billion to $87 billion and set non-GAAP earnings guidance at $35.50 to $36.50 a share.

Mounjaro and Zepbound drove the advance, showing that demand remains strong. The caveat is price. Lilly has reported lower realized prices in several markets even as volume expands. That can be a rational trade if access broadens and manufacturing becomes more efficient, but investors should track revenue growth against gross margin rather than assume every prescription adds the same economics.

The pipeline adds another layer. Lilly said the Phase 3 data package for retatrutide is complete for obesity, obstructive sleep apnea and knee osteoarthritis pain, with a U.S. filing planned for the first quarter of 2027. A filing is not an approval, and the product's commercial value will depend on label, safety, supply and reimbursement.

Capacity remains essential. Lilly committed another $4.5 billion to expand Indiana manufacturing sites, raising the burden on execution while addressing a real constraint. The company must bring plants online without sacrificing quality or letting demand shift to rivals.

Lilly's growth case is supported by reported sales, raised guidance and a late-stage pipeline. The risk is not a lack of demand. It is whether pricing, reimbursement and capital intensity allow that demand to produce durable margins at the scale now embedded in expectations.

Micron is investing in Indium Corporation's refining and manufacturing capacity in Rome, New York, targeting a small but strategically important link in the semiconductor supply chain.

Under the agreement, Micron will provide strategic funding for expanded production of high-purity materials and enter a long-term supply arrangement. The companies did not disclose the investment amount, contracted volumes or pricing. That makes the announcement a resilience measure rather than a quantifiable earnings catalyst.

Indium is used in compounds and interfaces across advanced electronics, including applications relevant to semiconductor manufacturing. Global refining capacity is concentrated, and export restrictions can turn a low-volume material into a production bottleneck. Building more domestic capacity can reduce exposure to transportation, trade-policy and single-region supply risks.

The project fits Micron's broader U.S. strategy but should not be confused with its much larger manufacturing commitments. Micron has discussed up to $250 billion of U.S. memory manufacturing and research investment through 2035. The Indium transaction supports the upstream materials base; it does not create a new memory fab or guarantee additional wafer output.

The timing is also long term. Capacity expansion, qualification and supply agreements take time, and neither company provided an expected production start in the announcement. Investors should look for commissioning milestones, qualified output and disclosure about how much of Micron's demand the agreement can cover.

The financial impact is likely modest relative to Micron's capital program. The strategic value lies in reducing the chance that a niche material disrupts much more expensive manufacturing assets. That is useful insurance, but the absent terms prevent a precise estimate of return.

Micron workers in Taoyuan, Taiwan, plan a one-day strike on October 22 after talks over bonuses and profit sharing failed to produce an agreement. The limited action is intended as a warning, but it touches a manufacturing base that is central to Micron's AI-memory growth.

The dispute is not simply about one annual payment. The union wants a clearer, permanent formula tied to profit and has criticized the predictability of Micron's bonus system. Earlier reporting said the unions sought quarterly bonuses linked to 15% of operating profit. Micron announced a T$1 million cash award for eligible Taiwan employees as part of its fiscal 2026 rewards, but the Taoyuan union said that did not resolve its structural demand.

Micron employs roughly 15,000 people in Taiwan and has invested more than T$1.6 trillion there. The company's Taichung operations include advanced assembly and testing for high-bandwidth memory, a component used in AI servers. Micron has said HBM capacity is fully booked through 2027.

A one-day stoppage does not by itself establish a material supply disruption. The effect depends on participation, inventory, which production steps are affected and whether the dispute spreads or repeats. No verified loss estimate is available, so investors should not convert the announcement into a precise revenue impact.

The investment risk is escalation. A negotiated formula could raise labor costs, while prolonged action could complicate output during a period of tight memory supply. The opportunity is resolution before either occurs. Investors should watch the October 22 participation rate, Taichung negotiations and any company disclosure about production rather than infer damage from the strike notice alone.

Coherent is selling more of the optical components that connect AI infrastructure, but its fiscal 2026 results also show the cost of expanding fast enough to meet that demand.

Fourth-quarter revenue reached $2.05 billion, up 34% from a year earlier. GAAP gross margin was 38.5%, and adjusted earnings were $1.74 a share. Management guided the following quarter to $2.2 billion to $2.4 billion of revenue and adjusted earnings of $1.85 to $2.05 a share.

Cash flow was the counterweight. Coherent reported about $79.5 million of operating cash flow for the full year while capital expenditure reached roughly $1.10 billion. That implies deeply negative free cash flow before considering other financing activities. The spending may support future capacity, but investors still need evidence that higher revenue can fund the buildout.

PhotonLink is part of that growth case. Coherent says the integrated optics platform addresses connections within and around AI systems and could add a $30 billion market opportunity by 2030. Revenue was expected to begin ramping in the fourth quarter of calendar 2026. Market-size estimates are management projections, not booked sales.

The competitive context is favorable but demanding. Nvidia's investment in Coherent and Lumentum included future access rights and purchase commitments, validating the strategic importance of photonics. It also raises expectations for delivery, yields and capacity.

For investors, the most useful scorecard is not a distant valuation model. It is quarterly revenue, gross margin, operating cash flow and capital spending, alongside disclosed PhotonLink customers and production milestones. Coherent has demonstrated demand and improving earnings. The unresolved question is when that growth becomes consistently self-financing.